Dovato have a growing wealth of Real-World Data that continues to reinforce robust efficacy in the switch to Dovato.
See the Real-World (new word) Data for both Naive and Switch PLHIV
Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
Recommended as an initial regimen for treatment-naïve patients and as a switch strategy for virologically suppressed patients7
Requirements for treatment-naïve patients:
Requirements for switch patients:
Recommended as an initial regimen for most people living with HIV (AI)* and as a good option for virologically suppressed patients who have no evidence of resistance to either drug8
Exclusions for treatment-naïve patients:
*Rating of recommendations: A=strong; B=moderate; C=optional. Rating of evidence: I=data from randomised controlled trials; II=data from well-designed non-randomised trials, observational cohort studies with long-term clinical outcomes, relative bioavailability/bioequivalence studies or regimen comparisons from randomised switch studies; III=expert opinion.8
Please refer to the latest DHHS guidelines for further information about treatment options.
Recommended as an initial regimen for most people with HIV and as an appropriate switch strategy for virologically suppressed patients (AIa)*9
Not recommended in:
Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.6
References:
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255, or via the online patient safety reporting form at gsk.public.reportum.com.
Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.
Date of preparation: April 2025 PM-IE-DLL-WCNT-200016